Form 4 for SLS SELLAS Life Sciences Group, Inc.
Accepted 2025-01-14 00:00:00 ET · period of report 2025-01-10 · accession 0001104659-25-003496 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-14 | 2025-01-10 | SLS | Kalin Katherine Bach | Dir | A - Grant | $0.00 | +12.5K | 21.0K | +147% | $0 |
| D | 2025-01-14 | 2025-01-10 | SLS | Kalin Katherine Bach | Dir | A - Grant | $0.00 | +18.5K | 18.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-10 | A | A | 12,500 | $0.00 | 21,000 | D | — | — | (F1) The Reporting Person received an award of 12,500 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-01-10 | A | A | 18,500 | $0.00 | 18,500 | D | $0.95 · — to 2035-01-10 | 18,500 Common Stock | (F2) The shares subject to the option will fully vest on the earlier of (x) January 10, 2026 (the first anniversary of the date of grant) or (y) the business day prior to the 2026 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |